The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome

Autoimmunity Reviews

Volumn 13, Issue 9, 2014, Pages 883-891

  Lega, Jean Christophe ^a   Fabien, Nicole ^a   Reynaud, Quitterie ^a   Durieu, Isabelle ^a   Durupt, Stéphane ^a   Dutertre, Marine ^a   Cordier, Jean François ^a   Cottin, Vincent ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Anti aminoacyl tRNA synthetase autoantibodies; Anti PM Scl autoantibodies; Interstitial lung disease; Myositis; Systemic sclerosis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AMINO ACID TRANSFER RNA LIGASE ANTIBODY; AUTOANTIBODY; JO 1 ANTIBODY; KU ANTIBODY; MI 2 ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; SCL AUTOANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; U 1 ANTIBODY; UNCLASSIFIED DRUG;

ANTISYNTHETASE SYNDROME; ARTHRALGIA; CLINICAL FEATURE; COHORT ANALYSIS; DERMATOMYOSITIS; EVIDENCE BASED PRACTICE; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; MYOSITIS; NEOPLASM; PHENOTYPE; RASH; RAYNAUD PHENOMENON; REVIEW; SCLERODACTYLY; SKIN DISEASE; STUDY DESIGN; IMMUNOLOGY; META ANALYSIS; MORTALITY;

AMINO ACYL-TRNA SYNTHETASES; AUTOANTIBODIES; COHORT STUDIES; HUMANS; MYOSITIS; PHENOTYPE;

EID: 84922640900     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.03.004     Document Type: Review

References (56)

1. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
2. Mammen A.L. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010, 1184:134-153.
3. Mahler M., Miller F.W., Fritzler M.J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014, 13:367-371.
4. Walker J.G., Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
5. Marguerie C., Bunn C.C., Beynon H.L., Bernstein R.M., Hughes J.M., So A.K., et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990, 77:1019-1038.
6. Vancsa A., Gergely L., Ponyi A., Lakos G., Nemeth J., Szodoray P., et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010, 77:125-130.
7. Selva-O'Callaghan A., Labrador-Horrillo M., Solans-Laque R., Simeon-Aznar C.P., Martinez-Gomez X., Vilardell-Tarres M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006, 55:791-798.
8. Hausmanowa-Petrusewicz I., Kowalska-Oledzka E., Miller F.W., Jarzabek-Chorzelska M., Targoff I.N., Blaszczyk-Kostanecka M., et al. Clinical, serologic, and-immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
9. Hervier B., Devilliers H., Stanciu R., Meyer A., Uzunhan Y., Masseau A., et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012, 12:210-217.
10. Aggarwal R., Cassidy E., Fertig N., Koontz D.C., Lucas M., Ascherman D.P., et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2013, 73:227-232.
11. Lega J.C., Cottin V., Fabien N., Thivolet-Bejui F., Cordier J.F. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?. J Rheumatol 2010, 37:1000-1009.
12. Marie I., Lahaxe L., Benveniste O., Delavigne K., Adoue D., Mouthon L., et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162:337-344.
13. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
14. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
15. Hengstman G.J., ter Laak H.J., Vree Egberts W.T., Lundberg I.E., Moutsopoulos H.M., Vencovsky J., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006, 65:1635-1638.
16. Hengstman G.J., Brouwer R., Egberts W.T., Seelig H.P., Jongen P.J., van Venrooij W.J., et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002, 249:69-75.
17. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Cucherat M., Boissel J.P., Leizorovicz A., Haugh M.C. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Prog Biomed 1997, 53:187-190.
20. Dugar M., Cox S., Limaye V., Blumbergs P., Roberts-Thomson P.J. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011, 41:674-679.
21. Brouwer R., Hengstman G.J.D., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
22. Chinoy H., Fertig N., Oddis C.V., Ollier W.E.R., Cooper R.G. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, 66:1345-1349.
23. Chinoy H., Salway F., Fertig N., Shephard N., Tait B.D., Thomson W., et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006, 8:R13.
24. Dieval C., Ribeiro E., Mercie P., Blanco P., Duffau P., Longy-Boursier M. Antisynthetase syndrome: a retrospective study of 14 patients. Rev Med Interne 2012, 33:76-79.
25. Ghirardello A., Rampudda M., Ekholm L., Bassi N., Tarricone E., Zampieri S., et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 2010, 49:2370-2374.
26. Hamaguchi Y., Kuwana M., Hoshino K., Hasegawa M., Kaji K., Matsushita T., et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011, 147:391-398.
27. Hirakata M., Mimori T., Akizuki M., Craft J., Hardin J.A., Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992, 35:449-456.
28. Ikeda N., Takahashi K., Yamaguchi Y., Inasaka M., Kuwana M., Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol 2011, 38:973-979.
29. Kang E.H., Nakashima R., Mimori T., Kim J., Lee Y.J., Lee E.B., et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 2010, 11:223.
30. Kao A.H., Lacomis D., Lucas M., Fertig N., Oddis C.V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004, 50:209-215.
31. Koenig M., Fritzler M.J., Targoff I.N., Troyanov Y., Senecal J.L. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007, 9:R78.
32. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991, 70:360-374.
33. Marie I., Josse S., Decaux O., Dominique S., Diot E., Landron C., et al. Comparison of long-term outcome between anti-Jo1-and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012, 11:739-745.
34. Matsushita T., Hasegawa M., Fujimoto M., Hamaguchi Y., Komura K., Hirano T., et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol 2007, 34:1012-1018.
35. Meyer O., Cremer-Legmann F., Haim T., Ryckewaert A. The principle antinuclear and anti-cytoplasmic antibodies in polymyositis and dermatomyositis. Study of 42 cases. Presse Med 1987, 16:155-158.
36. O'Hanlon T.P., Rider L.G., Schiffenbauer A., Targoff I.N., Malley K., Pandey J.P., et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008, 58:3239-3246.
37. Sato S., Hirakata M., Kuwana M., Suwa A., Inada S., Mimori T., et al. Autoantibodies to a 140-kD polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005, 52:1571-1576.
38. Troyanov Y., Targoff I.N., Tremblay J.L., Goulet J.R., Raymond Y., Senecal J.L. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
39. Yoshifuji H., Fujii T., Kobayashi S., Imura Y., Fujita Y., Kawabata D., et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006, 39:233-241.
40. Targoff I.N., Johnson A.E., Miller F.W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990, 33:1361-1370.
41. Hamaguchi Y., Fujimoto M., Matsushita T., Kaji K., Komura K., Hasegawa M., et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 2013, 8:e60442.
42. Fathi M., Vikgren J., Boijsen M., Tylen U., Jorfeldt L., Tornling G., et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008, 59:677-685.
43. Klein R.Q., Teal V., Taylor L., Troxel A.B., Werth V.P. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol 2007, 57:937-943.
44. Hausmanowa-Petrusewicz I., Kowalska-Oledzka E., Miller F.W., Jarzabek-Chorzelska M., Targoff I.N., Blaszczyk-Kostanecka M., et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
45. Friedman A.W., Targoff I.N., Arnett F.C. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996, 26:459-467.
46. Vazquez-Abad D., Rothfield N.F. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996, 39:292-296.
47. Schmidt W.A., Wetzel W., Friedlander R., Lange R., Sorensen H.F., Lichey H.J., et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies - an evolving spectrum of disease manifestations. Clin Rheumatol 2000, 19:371-377.
48. Targoff I.N., Arnett F.C., Berman L., O'Brien C., Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest 1989, 84:162-172.
49. Jablonska S., Chorzelski T.P., Blaszczyk M., Jarzabek-Chorzelska M., Kumar V., Beutner E.H. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol 1992, 10:457-472.
50. Hervier B., Devilliers H., Stanciu R., Meyer A., Uzunhan Y., Masseau A., et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2013, 12:210-217.
51. Hervier B., Meyer A., Dieval C., Uzunhan Y., Devilliers H., Launay D., et al. Pulmonary hypertension in antisynthetase syndrome: prevalence, etiology and survival. Eur Respir J 2013, 42:1271-1282.
52. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
53. Oddis C.V., Okano Y., Rudert W.A., Trucco M., Duquesnoy R.J., Medsger T.A. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211-1217.
54. Gendi N.S., Welsh K.I., Van Venrooij W.J., Vancheeswaran R., Gilroy J., Black C.M. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995, 38:259-266.
55. Briggs D.C., Vaughan R.W., Welsh K.I., Myers A., duBois R.M., Black C.M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991, 338:661-662.
56. Chinoy H., Payne D., Poulton K.V., Fertig N., Betteridge Z., Gunawardena H., et al. HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009, 48:1213-1217.